Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy (original) (raw)
Benowitz NL, Jacob III P . Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 1994; 56: 483–493. ArticleCASPubMed Google Scholar
Messina ES, Tyndale RF, Sellers EM . A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997; 282: 1608–1614. CASPubMed Google Scholar
Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K et al. Role of human cytochrome _P_4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996; 24: 1212–1217. CASPubMed Google Scholar
Dempsey D, Tutka P, Jacob III P, Allen F, Schoedel K, Tyndale RF et al. Nicotine metabolite ratio as an index of cytochrome _P_450 2A6 metabolic activity. Clin Pharmacol Ther 2004; 76: 64–72. ArticleCASPubMed Google Scholar
Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K et al. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 1010–1015. CASPubMed Google Scholar
Benowitz NL, Tyndale RF, Jacob III P, Swan GE . CYP2A6 polymorphisms and nicotine metabolism. Clin Pharmacol Ther 2002; 71: 41. Google Scholar
Xu C, Rao YS, Xu B, Hoffmann E, Jones J, Sellers EM et al. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun 2002; 290: 318–324. ArticleCASPubMed Google Scholar
Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers EM et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000; 58: 747–755. ArticleCASPubMed Google Scholar
Benowitz NL, Jacob III P . Nicotine renal excretion rate influences nicotine intake during cigarette smoking. J Pharmacol Exp Ther 1985; 234: 153–155. CASPubMed Google Scholar
Zacny JP, Stitzer ML . Cigarette brand-switching: effects on smoke exposure and smoking behavior. J Pharmacol Exp Ther 1988; 246: 619–627. CASPubMed Google Scholar
Nakajima M, Yamagishi S, Yamamoto H, Yamamoto T, Kuroiwa Y, Yokoi T . Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin Pharmacol Ther 2000; 67: 57–69. ArticleCASPubMed Google Scholar
Ariyoshi N, Miyamoto M, Umetsu Y, Kunitoh H, Dosaka-Akita H, Sawamura Y et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol Biomarkers Prev 2002; 11: 890–894. CASPubMed Google Scholar
Iwahashi K, Waga C, Takimoto T . Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior. Neuropsychobiology 2004; 49: 101–104. ArticleCASPubMed Google Scholar
Minematsu N, Nakamura H, Iwata M, Tateno H, Nakajima T, Takahashi S et al. Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema. Thorax 2003; 58: 623–628. ArticleCASPubMedPubMed Central Google Scholar
Schoedel K, Hoffmann E, Rao Y, Sellers E, Tyndale RF . Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004; 14: 615–626. ArticleCASPubMed Google Scholar
Goodz S, Alhuwalia J, Harris K, Xu C, Rao YS, Xu B et al. CYP2A6 genetic variants among African-Americans. Abstract presentation at the Society for Research on Nicotine and Tobacco meeting, Savanna, GA, 2002 (Published only in meeting proceedings).
Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 2004; 25: 2451–2458. ArticleCASPubMed Google Scholar
London SJ, Idle JR, Daly AK, Coetzee GA . Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 1999; 353: 898–899. ArticleCASPubMed Google Scholar
Loriot MA, Rebuissou S, Oscarson M, Cenee S, Miyamoto M, Ariyoshi N et al. Genetic polymorphisms of cytochrome _P_450 2A6 in a case–control study on lung cancer in a French population. Pharmacogenetics 2001; 11: 39–44. ArticleCASPubMed Google Scholar
Sabol SZ, Hamer DH . An improved assay shows no association between the CYP2A6 gene and cigarette smoking behaviour. Behav Genet 1999; 157: 632–634. Google Scholar
Ando M, Hamajima N, Ariyoshi N, Kamataki T, Matsuo K, Ohno Y . Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults. J Epidemiol 2003; 13: 176–181. ArticlePubMed Google Scholar
O'Loughlin J, Paradis G, Kim W, DiFranza J, Meshefedjian G, McMillan-Davey E et al. Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tobacco Control 2004; 13: 422–428. ArticleCASPubMedPubMed Central Google Scholar
McGoven PG, Lando HA, Roski J, Pirie PL, Sprafka JM . A comparison of smoking cessation clinic participants with smokers in the general population. Tobacco Control 1994; 3: 329–333. ArticlePubMed Central Google Scholar
Fagerstrom KO, Kunze M, Schoberberger R, Breslau N, Hughes JR, Hurt RD et al. Nicotine dependence versus smoking prevalence: comparisons among countries and categories of smokers. Tobacco Control 1996; 5: 52–56. ArticleCASPubMedPubMed Central Google Scholar
Fiore MC . US public health service clinical practice guideline: treating tobacco use and dependence. Respir Care 2000; 45: 1200–1262. CASPubMed Google Scholar
Fant RV, Owen LL, Henningfield JE . Nicotine replacement therapy. Primary Care 1999; 26: 633–652. ArticleCASPubMed Google Scholar
Levin ED, Westman EC, Stein RM, Carnahan E, Sanchez M, Herman S et al. Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. J Clin Psychopharmacol 1994; 14: 41–49. ArticleCASPubMed Google Scholar
Benowitz NL, Zevin S, Jacob III P . Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. Br J Clin Pharmacol 1997; 43: 259–267. ArticleCASPubMedPubMed Central Google Scholar
Hurt RD, Dale LC, Offord KP, Lauger GG, Baskin LB, Lawson GM et al. Serum nicotine and cotinine levels during nicotine-patch therapy. Clin Pharmacol Ther 1993; 54: 98–106. ArticleCASPubMed Google Scholar
Jones RL, Nguyen A, Man SF . Nicotine and cotinine replacement when nicotine nasal spray is used to quit smoking. Psychopharmacology (Berlin) 1998; 137: 345–350. ArticleCAS Google Scholar
Xu C, Goodz S, Sellers EM, Tyndale RF . CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev 2002; 54: 1245–1256. ArticleCASPubMed Google Scholar
Malaiyandi V, Sellers EM, Tyndale RF . Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 2005; 77: 145–158. ArticleCASPubMed Google Scholar
Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR . High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA 1995; 274: 1353–1358. ArticleCASPubMed Google Scholar
Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP, Croghan IT et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995; 274: 1347–1352. ArticleCASPubMed Google Scholar
Hadidi H, Zahlsen K, Idle JR, Cholerton S . A single amino acid substitution (Leu160His) in cytochrome _P_450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem Toxicol 1997; 35: 903–907. ArticleCASPubMed Google Scholar
Kiyotani K, Yamazaki H, Fujieda M, Iwano S, Matsumura K, Satarug S et al. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics 2003; 13: 689–695. ArticleCASPubMed Google Scholar
Oscarson M, McLellan RA, Asp V, Ledesma M, Ruiz ML, Sinues B et al. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat 2002; 20: 275–283. ArticleCASPubMed Google Scholar
Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001; 69: 72–78. ArticleCASPubMed Google Scholar
Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon JT, Yokoi T . Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003; 74: 69–76. ArticleCASPubMed Google Scholar
Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann Intern Med 2004; 140: 426–433. ArticleCASPubMed Google Scholar
Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenom J 2004; 4: 184–192. ArticleCAS Google Scholar
Benowitz NL, Perez-Stable EJ, Fong I, Modin G, Herrera B, Jacob III P . Ethnic differences in _N_-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 1999; 291: 1196–1203. CASPubMed Google Scholar
Haberl M, Anwald B, Klein K, Weil R, Fu C, Gepdiremen A et al. Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet Genomics 2005; 15: 609–624. ArticleCASPubMed Google Scholar
Hukkanen J, Jacob III P, Benowitz NL . Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005; 57: 79–115. ArticleCASPubMed Google Scholar
Gu DF, Hinks LJ, Morton NE, Day IN . The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 2000; 64: 383–390. ArticleCASPubMed Google Scholar
Broms U, Silventoinen K, Lahelma E, Koskenvuo M, Kaprio J . Smoking cessation by socioeconomic status and marital status: the contribution of smoking behavior and family background. Nicotine Tobacco Res 2004; 6: 447–455. Article Google Scholar
Ferguson JA, Patten CA, Schroeder DR, Offord KP, Eberman KM, Hurt RD . Predictors of 6-month tobacco abstinence among 1224 cigarette smokers treated for nicotine dependence. Addict Behav 2003; 28: 1203–1218. ArticlePubMed Google Scholar
McKee SA, O'Malley SS, Salovey P, Krishnan-Sarin S, Mazure CM . Perceived risks and benefits of smoking cessation: gender-specific predictors of motivation and treatment outcome. Addict Behav 2005; 30: 423–435. ArticlePubMed Google Scholar
Perkins KA . Smoking cessation in women. Special considerations. CNS Drugs 2001; 15: 391–411. ArticleCASPubMed Google Scholar
Westmaas JL, Langsam K . Unaided smoking cessation and predictors of failure to quit in a community sample: effects of gender. Addict Behav 2005; 30: 1405–1424. ArticlePubMed Google Scholar
Batra V, Patkar AA, Berrettini WH, Weinstein SP, Leone FT . The genetic determinants of smoking. Chest 2003; 123: 1730–1739. ArticleCASPubMed Google Scholar
Lerman C, Berrettini W . Elucidating the role of genetic factors in smoking behavior and nicotine dependence. Am J Med Genet 2003; 118B: 48–54. ArticlePubMed Google Scholar
Daughton DM, Fortmann SP, Glover ED, Hatsukami DK, Heatley SA, Lichtenstein E et al. The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4–5 years post-quit day. Prev Med 1999; 28: 113–118. ArticleCASPubMed Google Scholar
Law MR, Morris JK, Watt HC, Wald NJ . The dose–response relationship between cigarette consumption, biochemical markers and risk of lung cancer. Br J Cancer 1997; 75: 1690–1693. ArticleCASPubMedPubMed Central Google Scholar
Strasser AA, Kaufmann V, Jepson C, Perkins KA, Pickworth WB, Wileyto EP et al. Effects of different nicotine replacement therapies on postcessation psychological responses. Addict Behav 2005; 30: 9–17. ArticlePubMed Google Scholar
Strasser AA, Malaiyandi V, Lerman C, Tyndale RF . Differences in smoking topography associated with CYP2A6 genotype. Soc Res Nicotine Tobacco 2005; 7: 704. Google Scholar
Benowitz NL, Kuyt F, Jacob III P . Circadian blood nicotine concentrations during cigarette smoking. Clin Pharmacol Ther 1982; 32: 758–764. ArticleCASPubMed Google Scholar
Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob III P . Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tobacco Res 2003; 5: 621–624. ArticleCAS Google Scholar
Jarvik ME, Madsen DC, Olmstead RE, Iwamoto-Schaap PN, Elins JL, Benowitz NL . Nicotine blood levels and subjective craving for cigarettes. Pharmacol Biochem Behav 2000; 66: 553–558. ArticleCASPubMed Google Scholar
Zubieta JK, Heitzeg MM, Xu Y, Koeppe RA, Ni L, Guthrie S et al. Regional cerebral blood flow responses to smoking in tobacco smokers after overnight abstinence. Am J Psychiatry 2005; 162: 567–577. ArticlePubMed Google Scholar
Balfour D, Benowitz N, Fagerstrom K, Kunze M, Keil U . Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report. Eur Heart J 2000; 21: 438–445. ArticleCASPubMed Google Scholar
George TP, O'Malley SS . Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 2004; 25: 42–48. ArticleCASPubMed Google Scholar
Gourlay SG, Benowitz NL, Forbes A, McNeil JJ . Determinants of plasma concentrations of nicotine and cotinine during cigarette smoking and transdermal nicotine treatment. Eur J Clin Pharmacol 1997; 51: 407–414. ArticleCASPubMed Google Scholar
Runkel M, Bourian M, Tegtmeier M, Legrum W . The character of inhibition of the metabolism of 1,2-benzopyrone (coumarin) by grapefruit juice in human. Eur J Clin Pharmacol 1997; 53: 265–269. ArticleCASPubMed Google Scholar
Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA et al. Effects of prototypical microsomal enzyme inducers on cytochrome _P_450 expression in cultured human hepatocytes. Drug Metab Dispos 2003; 31: 421–431. ArticleCASPubMed Google Scholar